3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
23
Myelodysplastic Syndromes
14
Leukemia, Myelomonocytic, Chronic
7
Myeloproliferative Disorders
4
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Biphenotypic, Acute
2
Anemia, Refractory, with Excess of Blasts
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
BRCA1 Mutation
1
Interventions
lutetium Lu 177 dotatate
21
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
Capecitabine
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
olaparib
4
amino-acid, glucose, and electrolyte solution
4
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
1 year
×
Clear all
NCT05178693
2025-11-24
LANTana
Imperial College London
Phase 1
Recruiting
27 enrolled